Press Release Archives - Metrion Biosciences

Metrion Biosciences Appoints Mark Keogh as Non-Executive Director

Sophie Rose2021-04-19T08:01:56+00:00

Metrion Biosciences appoints Mark Keogh as Non-Executive Director Appointment strengthens the financial and corporate experience of Metrion’s Board in support of the Company’s planned international growth Cambridge, UK, 19 April 2021: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Mark Keogh as a [...]

Metrion Biosciences Appoints Mark Keogh as Non-Executive DirectorSophie Rose2021-04-19T08:01:56+00:00

Metrion Biosciences closes £2.7m new equity financing

Sophie Rose2021-04-06T07:59:45+00:00

Metrion Biosciences closes £2.7m new equity financing • Financing led by Gresham House Ventures • Funds to be used to enhance Metrion’s Cambridge, UK ion channel drug discovery laboratories and capabilities and expand its presence in the USA • Maya Ward, Associate Director, Gresham House Ventures, appointed to Metrion Board of Directors Cambridge, UK, [...]

Metrion Biosciences closes £2.7m new equity financingSophie Rose2021-04-06T07:59:45+00:00

Metrion Biosciences appoints John Montana as Non-Executive Director

Sophie Rose2021-02-09T09:05:37+00:00

Metrion Biosciences appoints John Montana as Non-Executive Director Expansion of the Board of Directors will support the company’s further growth as an ion channels focused drug discovery CRO Cambridge, UK, 09 February 2021: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of John Montana, [...]

Metrion Biosciences appoints John Montana as Non-Executive DirectorSophie Rose2021-02-09T09:05:37+00:00

Metrion Biosciences and Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration

Sophie Rose2021-02-01T08:45:23+00:00

Metrion Biosciences and Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration • Ion channels represent a large but under-exploited class of drug targets beyond G protein-coupled receptors (GPCRs) • Collaboration combines Sosei Heptares’ leading structure-based drug design platform with Metrion Biosciences’ ion channel expertise • Joint [...]

Metrion Biosciences and Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology CollaborationSophie Rose2021-02-01T08:45:23+00:00

Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration

Sophie Rose2021-01-18T09:56:07+00:00

Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration Ongoing collaboration extended for another 12 months and successfully progresses into late stage hit-to-lead optimisation phase Cambridge and London, UK, 18 January 2021: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent [...]

Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaborationSophie Rose2021-01-18T09:56:07+00:00

Metrion Biosciences Strengthens Global Business Development Team

Sophie Rose2020-11-09T20:37:07+00:00

Two appointments in USA and Europe increase representation across key regions Partnership established with On Target Drug Discovery Service and Supply, Ltd. to represent Metrion in Japan Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has significantly enhanced its global business development capabilities, with additional resources [...]

Metrion Biosciences Strengthens Global Business Development TeamSophie Rose2020-11-09T20:37:07+00:00

Metrion Biosciences and International Scientific Consortium publish data and new recommendations for in vitro risk assessment of the cardiac safety of new medicines

Sophie Rose2020-05-11T12:31:08+00:00

Metrion Biosciences and International Scientific Consortium publish data and new recommendations for in vitro risk assessment of the cardiac safety of new medicines Part of the US FDA’s Comprehensive in vitro Proarrythmia Assay (CiPA) Initiative Cambridge, UK, 07 April 2020: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today [...]

Metrion Biosciences and International Scientific Consortium publish data and new recommendations for in vitro risk assessment of the cardiac safety of new medicinesSophie Rose2020-05-11T12:31:08+00:00

Metrion Biosciences and LifeArc extend ion channel drug discovery collaboration

Sophie Rose2019-12-03T08:32:31+00:00

Metrion Biosciences and LifeArc extend ion channel drug discovery collaboration to accelerate neuroscience-focused research Initial twelve month collaboration successfully identifies hit compounds and progresses into hit-to-lead optimisation phase Cambridge and London, UK, 03 December 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical [...]

Metrion Biosciences and LifeArc extend ion channel drug discovery collaborationSophie Rose2019-12-03T08:32:31+00:00

Metrion Biosciences Appoints Dr Andrew Southan as Chief Executive Officer

Sophie Rose2019-04-08T08:01:46+00:00

Metrion Biosciences Appoints Dr Andrew Southan as Chief Executive Officer Cambridge, UK, 08 April 2019: Metrion Biosciences (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief Operating Officer. Dr Southan joined [...]

Metrion Biosciences Appoints Dr Andrew Southan as Chief Executive OfficerSophie Rose2019-04-08T08:01:46+00:00

Metrion Biosciences closes funding round

Sophie Rose2019-04-01T08:22:36+00:00

Metrion Biosciences Closes Funding Round Includes investment from o2h Ventures Therapeutics Fund Funding to support expansion of ion channel screening capabilities and continued research into potential drugs for auto-immune diseases Cambridge, UK, 01 April 2019: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, announced today that it has completed [...]

Metrion Biosciences closes funding roundSophie Rose2019-04-01T08:22:36+00:00